Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000728702 | SCV000856307 | uncertain significance | not provided | 2017-08-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002067089 | SCV002425155 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-11-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002422625 | SCV002718968 | likely benign | Cardiovascular phenotype | 2022-08-16 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004547921 | SCV004708436 | likely benign | JAG1-related disorder | 2021-05-07 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |